Tisdag 10 November | 06:33:26 Europe / Stockholm
Svenska | English
Kursutveckling under dagen för detta pressmeddelande (SEK).
Likviditet under dagen för detta pressmeddelande
Est. tid*
2027-11-04 08:00 Kvartalsrapport 2027-Q3
2027-08-26 08:00 Kvartalsrapport 2027-Q2
2027-04-29 08:00 Kvartalsrapport 2027-Q1
2027-02-12 08:00 Bokslutskommuniké 2026
2026-11-05 - Kvartalsrapport 2026-Q3
2026-08-27 - Kvartalsrapport 2026-Q2
2026-05-13 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2026-05-12 - Årsstämma
2026-04-29 - Kvartalsrapport 2026-Q1
2026-02-19 - Bokslutskommuniké 2025
2025-11-06 - Kvartalsrapport 2025-Q3
2025-08-27 - Kvartalsrapport 2025-Q2
2025-05-16 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2025-05-15 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-19 - Bokslutskommuniké 2024
2025-02-13 - Extra Bolagsstämma 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-20 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-09 - Årsstämma
2023-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-10-25 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-10 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2022-06-09 - Årsstämma
2022-04-20 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2020-06-02 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-06-12 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2019-06-11 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-12 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2018-05-29 - Årsstämma
2018-05-15 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-10-23 - Extra Bolagsstämma 2017
2017-08-24 - Kvartalsrapport 2017-Q2
2017-06-13 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2017-06-12 - Årsstämma
2017-05-17 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-27 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2016-05-26 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-06 - Extra Bolagsstämma 2016
2016-02-25 - Bokslutskommuniké 2015
2015-11-19 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Nanexa är ett drug delivery-bolag med en egenutvecklad plattform som används för formulering av injicerbara depåläkemedel som skapar en tillförsel av läkemedel till blodet. Bolagets teknologi baseras på att innesluta läkemedelspartiklar med ett tunt skal och skapa möjlighet för läkemedelsbolag att utveckla nya produkter. Nanexa har samarbete med flertalet läkemedelsbolag, huvudsakligen runtom den nordiska marknaden.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Nanexa publishes interim report for July-September 2026

2026-11-05 08:00:00

A strategically important third quarter for Nanexa, marked by an agreement with Novo and scientific and operational progress

Significant events during the third quarter of 2026

  • Nanexa announced on September 24 a global license and collaboration agreement with Novo for long-acting injectables. The agreement is valued at EUR 1.165 billion, including an upfront payment of EUR 20 million, followed by EUR 595 million in development and regulatory milestone payments. The remaining milestone payments are sales related. In addition, Nanexa is entitled to a low single-digit royalty on global net sales of products developed under the agreement. The agreement grants Novo a global exclusive license to Nanexa’s proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases.
  • Nanexa announced on September 22 a joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicines with Forge Nano. Collaboration intends to develop large-scale, GMP-compliant ALD manufacturing equipment supporting Nanexa’s broad portfolio of proprietary and partnered PharmaShell® programs.

Financial overview

1 July - 30 September 2026

  • Turnover amounted to: TSEK 227,865 (477)
  • Operating profit (EBIT) amounted to: TSEK 157,332 (-11,983)
  • Profit after tax amounted to: TSEK 157,384 (-12,538)
  • Earnings per share before dilution amounted to: SEK 0.82 (-0.08) SEK
  • Earnings per share after dilution amounted to: SEK 0.80 (-0.07) SEK
  • Cash flow for the period amounted to: TSEK -8,524 (-15,483)
  • Cash and cash equivalents at end of period: TSEK 44,033 (24,779)

Figures in brackets refer to the corresponding period in the previous year.

The entire report is available on the company’s website: https://nanexa.com/en/financial-reports/.

Report commentary, November 5 at 10:30 CET

A live commentary with CEO David Westberg will take place on November 5 at 10:30 CET via Infront Direkt Studios and viewers will have the opportunity to ask questions via chat. The presentation will be held in Swedish.

The report commentary will be available via this link

The report commentary will also be published on Nanexa's website afterwards.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se

The company’s Certified Adviser is Tapper Partners AB.

About Nanexa AB (publ)

Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others.
Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

This information is information that Nanexa is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-05 08:00 CET.

Attachments

Nanexa AB Interim Report July Sept 2026

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden